Related Experiment Videos
Developmental toxicity of metal chelating agents
1Laboratory of Toxicology and Environmental Health, School of Medicine, Rovira i Virgili University, Reus, Spain.
Reproductive Toxicology (Elmsford, N.Y.)
|October 8, 1998
Summary
Chelation therapy treats metal poisoning, but some agents pose developmental risks, especially for pregnant women. Careful risk-benefit assessment is crucial for controversial chelators.
Area of Science:
- Toxicology
- Pharmacology
- Developmental Biology
Background:
- Chelation therapy is a cornerstone for treating metal poisoning.
- Established chelating agents have been in use since the 1950s.
- Assessing developmental toxicity is critical as chelators may be administered to pregnant individuals.
Purpose of the Study:
- To review the developmental toxicity of clinically relevant chelating agents.
- To categorize chelators based on structural similarities.
- To discuss the role of trace element deficiencies in chelator-induced teratogenicity.
Main Methods:
- Categorization of chelating agents by structural class (e.g., polyaminocarboxylic acids, vicinal -SH group chelators).
- Review of experimental data on embryo/fetal toxic effects of various chelators.
- Analysis of the link between induced trace element deficiencies and teratogenic potential.
Main Results:
- Developmental toxicities of some chelators occur at doses exceeding therapeutic levels.
- The use of other metal antidotes presents controversial findings regarding safety.
- Teratogenic potential is often linked to induced trace element deficiencies.
Conclusions:
- The developmental toxicity profiles of clinical chelators vary.
- Careful consideration of benefits versus risks is necessary for controversial agents.
- Mineral supplementation may be advisable during chelation treatment to counteract induced deficiencies.